Chemomab Therapeutics

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts”— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City.

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Oral presentation at AASLD highlights broad clinical activity of Chemomab's CM-101 across multiple biomarkers and its disease-modifying potential in PSC

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab Therapeutics (NASDAQ: CMMB ) just reported results for the second quarter of 2024. Chemomab Therapeutics reported earnings per share of -26 cents.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —New Translational Data Further Confirms CM-101's Disease Modifying Activity in Primary Sclerosing Cholangitis— TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clinical rationale for the company's primary sclerosing cholangitis (PSC) program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy.

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

After reaching an important support level, Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) could be a good stock pick from a technical perspective.

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publications Based on Patient Sample Studies Further Reinforce the Key Role of Chemomab's Novel CCL24 Target in Both PSC and Systemic Sclerosis─ ─PSC Expert Webinar Highlights the Emerging Importance of Surrogate Biomarkers in PSC Clinical Development─ TEL AVIV, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain compliance with Nasdaq's minimum $1.00 bid price per share requirement.

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET.

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025 ─ ─Cash Runway Extended through End of First Quarter 2025 as a Result of Early Completion of Phase 2 PSC Trial and Effective Financial Management─  ─2023 Achievements Position Chemomab for a Potentially Transformational 2024─ TEL AVIV, Israel , March 7, 2024 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the full year and fourth quarter ended December 31, 2023, and provided a corporate update.

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor will deliver a corporate presentation and participate in investor meetings at the Leerink Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida.

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— — New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition of Matter and for Use in Fibrotic Diseases of the Liver, including PSC— —Further Extend Protections Afforded by Multiple CM-101 Patents that Have Issued in the U.S., Europe, Israel and Related Territories— TEL AVIV, Israel , Feb. 20, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation.

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time.

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences.

News for Chemomab Therapeutics Stock (CMMB)